CA
NPCE icon

Clearstead Advisors’s Neuropace NPCE Stock Holding History

Clearstead Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Buy
+2
New +$32 ﹤0.01% 3543

Other funds holding NPCE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $598M AUM 32.4% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clearstead Advisors's NPCE Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Neuropace (NPCE) in Q2 2026: 2 shares worth $32. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings.

30 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Clearstead Advisors held 2 shares of Neuropace worth $32 as of Q2 2026.
  • Neuropace was a new Clearstead Advisors position in Q2 2026.
  • Neuropace made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3543 holding.
  • 30 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.